Back
Janux Therapeutics, Inc. 10K Form
Sell
32
JANX
Janux Therapeutics, Inc.
Last Price:
$16.39
Seasonality Move:
94.45%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive JANX News And Ratings
See the #1 stock for the next 7 days that we like better than JANX
JANX Financial Statistics
Sales & Book Value
| Annual Sales: | $10.6M |
|---|---|
| Cash Flow: | $-12.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $16.24 |
| Price / Book: | 1.01 |
Profitability
| EPS (TTM): | -1.67510 |
|---|---|
| Net Income (TTM): | $-101.9M |
| Gross Margin: | $8.5M |
| Return on Equity: | -10.94% |
| Return on Assets: | -10.47% |
Janux Therapeutics, Inc. Earnings Forecast
Key Janux Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 6 years for JANX is 80.54%.
-
The Selling, General & Administrative Expenses for JANX have been equal to 387.67% of Gross Profit Margin.
-
The Research & Development expenses have been 645.90% of Revenue.
-
The Net Earning history of JANX is -651.62% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 2 years.
Janux Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | JANX |
| Website: | januxrx.com |
Debt
| Debt-to-Equity Ratio: | 0.02 |
|---|---|
| Current Ratio: | 35.86 |
| Quick Ratio: | 35.54 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
JANX Technical Analysis vs Fundamental Analysis
Sell
32
Janux Therapeutics, Inc. (JANX)
is a Sell
Is Janux Therapeutics, Inc. a Buy or a Sell?
-
Janux Therapeutics, Inc. stock is rated a SellThe current Janux Therapeutics, Inc. [JANX] share price is $16.40. The Score for JANX is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.